Effect of Early, Pre-Hospital Initiation of High Bolus Dose Tirofiban in Patients With ST-Segment Elevation Myocardial Infarction on Short- and Long-Term Clinical Outcome
Key result
Pre-hospital high bolus dose tirofiban reduces 30-day MACE by ~33% vs control in STEMI.
- P=0.043
- n=1,398
Why the study?
Does early, pre-hospital initiation of high bolus dose tirofiban reduce major adverse cardiac events in patients with STEMI undergoing primary PCI?
Population
1,398 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary…
Comparison
Early, pre-hospital initiation of high bolus… vs No tirofiban or placebo in addition to aspirin…
Design
RCT, randomized, open-label phase, followed by a double-blind…
Follow-up
30 days and 1 year
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
DRDawson ReimerPresident and COO, Medicure Inc.
“We have received substantial feedback from physicians that there is a need for more potent antiplatelet therapy when treating STEMI patients undergoing percutaneous coronary intervention. We believe the STEMI indication would increase the utility of AGGRASTAT for physicians, and thereby increase hospital adoption and demand.”
“We are evaluating the FDA's response and will work closely with the Agency to address their comments. In the meantime, AGGRASTAT continues to be the fastest growing GPI in the United States.”
Implication
Early pre-hospital administration of high bolus dose tirofiban, added to standard therapy, reduces 30-day major adverse cardiac events in STEMI patients undergoing primary PCI.
Key Points
- To determine whether initiating high bolus dose tirofiban in the pre-hospital setting improves short- and long-term clinical outcomes in patients suffering from ST-segment elevation myocardial infarction (STEMI).
- Evaluated patients presenting with STEMI who received high bolus dose tirofiban administration prior to hospital arrival.
- Assessed clinical outcomes across both acute post-procedural phases and extended long-term follow-up intervals.
- Early pre-hospital administration of high-dose tirofiban was evaluated for its efficacy in facilitating rapid coronary reperfusion and reducing ischemic events.
- Long-term assessment focused on rates of recurrent adverse cardiac events, overall survival, and safety outcomes including bleeding risks.
Study Design
Type
RCT (n=1,398)
Blinding
Open-label and double-blind phases
Randomization
Randomized
Structured PICO
Does early, pre-hospital initiation of high bolus dose tirofiban reduce major adverse cardiac events in patients with STEMI undergoing primary PCI?
P
Population
1,398 patients with STEMI undergoing primary percutaneous coronary intervention, followed for up to 1 year.
I
Intervention
Early, pre-hospital initiation of high bolus dose (HBD) tirofiban in addition to aspirin, heparin, and high-dose clopidogrel
C
Comparator
No tirofiban (phase 1) or placebo (phase 2) in addition to aspirin, heparin, and high-dose clopidogrel
O
Outcome
Incidence of major adverse cardiac events at the 30-day follow-upcomposite
Main Result
Absolute Event Rate: 5.8% vs 8.6%
p-value: p=0.043
Early pre-hospital administration of high bolus dose tirofiban, added to standard therapy, reduces 30-day major adverse cardiac events in STEMI patients undergoing primary PCI.
Cite This Study
Berg et al. (2010) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=1,398). High bolus dose tirofiban vs. No tirofiban or placebo was evaluated on Major adverse cardiac events at 30 days (p=0.043). Early, pre-hospital initiation of high bolus dose tirofiban significantly reduced major adverse cardiac events at 30 days compared to control (5.8% vs. 8.6%, p=0.043) in patients with STEMI.